115 related articles for article (PubMed ID: 7669515)
1. Clinical trials referral resource. Trials of topotecan.
Cheson BD; Phillips PH; Arbuck SG
Oncology (Williston Park); 1995 Mar; 9(3):220, 224-6, 228. PubMed ID: 7669515
[No Abstract] [Full Text] [Related]
2. Clinical trials referral resource. Clinical trials with topotecan.
Cheson BD; Arbuck SG
Oncology (Williston Park); 1993 Feb; 7(2):49-51. PubMed ID: 8439468
[No Abstract] [Full Text] [Related]
3. Topotecan in advanced colorectal cancer.
Creemers GJ
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-42-S20-48. PubMed ID: 9425960
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials referral resource. Clinical trials with 9-aminocamptothecin.
Oncology (Williston Park); 1995 Aug; 9(8):727-31. PubMed ID: 7577373
[No Abstract] [Full Text] [Related]
6. Topotecan hydrochloride for metastatic ovarian cancer.
Med Lett Drugs Ther; 1996 Oct; 38(986):96-7. PubMed ID: 8906133
[No Abstract] [Full Text] [Related]
7. The clinical pharmacology of topoisomerase I inhibitors.
Abang AM
Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
[TBL] [Abstract][Full Text] [Related]
8. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
Saltz L; Janik JE
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
[TBL] [Abstract][Full Text] [Related]
9. Topotecan in the treatment of gynecologic cancer.
Coleman RL; Miller DS
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
[TBL] [Abstract][Full Text] [Related]
10. Topotecan: an important new drug in the management of ovarian cancer.
Markman M
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-1. PubMed ID: 9122736
[No Abstract] [Full Text] [Related]
11. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
12. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
13. New cytotoxic drugs in clinical development.
Extra JM; Rousseau F; Culine S; Giacchetti S; Madelaine I; Marty M
Nouv Rev Fr Hematol (1978); 1991; 33(6):451-6. PubMed ID: 1687829
[No Abstract] [Full Text] [Related]
14. Review of phase I clinical studies with topotecan.
Rowinsky EK; Verweij J
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-3-S20-10. PubMed ID: 9425956
[TBL] [Abstract][Full Text] [Related]
15. Second-line therapy.
Nurs Stand; 1997 Feb; 11(21):28. PubMed ID: 9110778
[No Abstract] [Full Text] [Related]
16. [Development of cancer chemotherapy. Discovery of new active drugs. IV].
Lopez M
Clin Ter; 1999; 150(3):241-9. PubMed ID: 10528439
[No Abstract] [Full Text] [Related]
17. Clinical trials referral resource. Clinical trials using edatrexate.
Cheson BD; Sorenson JM; Phillips PH
Oncology (Williston Park); 1993 Jul; 7(7):33-4. PubMed ID: 8347459
[No Abstract] [Full Text] [Related]
18. Clinical trials referral resource. Clinical trials of dolastatin-10.
Wright JJ; Blatner G; Cheson BD
Oncology (Williston Park); 1999 Jan; 13(1):68-70, 75. PubMed ID: 10027199
[No Abstract] [Full Text] [Related]
19. Topotecan now available for HIV, PML research.
AIDS Treat News; 1995 Apr; (no 220):4. PubMed ID: 11362319
[TBL] [Abstract][Full Text] [Related]
20. Topotecan research moves forward at last.
Smart T
GMHC Treat Issues; 1995 Apr; 9(4):1-3. PubMed ID: 11362363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
